SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of
1934
ESSA Pharma Inc.
(Name of Issuer
- as specified in its charter)
Common Shares
(Title
of Class of Securities)
29668H708
(CUSIP
Number)
Peter J. Luiso, Esq.
Chief Compliance Officer and General Counsel
Eventide Asset Management, LLC
One International Place, Suite 4210
Boston, Massachusetts 02110
(877) 771- 3836
(Name,
Address and Telephone Number of Person Authorized to Receive Notices and Communications)
May 14, 2019
(Date of Event
which Requires Filing of this Statement)
If the filing person has previously filed
a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because
of Rule 13d-1(e)(f) or (g), check the following.
þ
*The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for
any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder
of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions
of the Act (however, see the Notes).
1
|
NAME OF REPORTING PERSON
Eventide Asset Management, LLC
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
¨
(a)
¨
(b)
|
3
|
SEC USE ONLY
|
4
|
SOURCE OF FUNDS
OO
|
5
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e)
¨
|
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
7
|
SOLE VOTING POWER
1,385,970
|
8
|
SHARED VOTING POWER
0
|
9
|
SOLE DISPOSITIVE POWER
1,385,970
|
10
|
SHARED DISPOSITIVE POWER
0
|
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,385,970
|
12
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES
¨
|
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
19.2%
|
14
|
TYPE OF REPORTING PERSON
IA
|
|
|
|
|
1
|
NAME OF REPORTING PERSON
Finny Kuruvilla, M.D. Ph.D.
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
¨
(a)
¨
(b)
|
3
|
SEC USE ONLY
|
4
|
SOURCE OF FUNDS
OO
|
5
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e)
¨
|
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
United States
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
7
|
SOLE VOTING POWER
0
|
8
|
SHARED VOTING POWER
1,385,970
|
9
|
SOLE DISPOSITIVE POWER
0
|
10
|
SHARED DISPOSITIVE POWER
1,385,970
|
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,385,970
|
12
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES
¨
|
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
19.2%
|
14
|
TYPE OF REPORTING PERSON
IN;HC
|
|
|
|
|
1
|
NAME OF REPORTING PERSON
Eventide Healthcare & Life Sciences Fund
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
¨
(a)
¨
(b)
|
3
|
SEC USE ONLY
|
4
|
SOURCE OF FUNDS
OO
|
5
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e)
¨
|
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Ohio
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
7
|
SOLE VOTING POWER
0
|
8
|
SHARED VOTING POWER
766,996
|
9
|
SOLE DISPOSITIVE POWER
0
|
10
|
SHARED DISPOSITIVE POWER
766,996
|
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
766,996
|
12
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES
¨
|
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
10.6%
|
14
|
TYPE OF REPORTING PERSON
IV
|
|
|
|
|
1
|
NAME OF REPORTING PERSON
Eventide Gilead Fund
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
¨
(a)
¨
(b)
|
3
|
SEC USE ONLY
|
4
|
SOURCE OF FUNDS
OO
|
5
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e)
¨
|
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Ohio
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
7
|
SOLE VOTING POWER
0
|
8
|
SHARED VOTING POWER
618,974
|
9
|
SOLE DISPOSITIVE POWER
0
|
10
|
SHARED DISPOSITIVE POWER
618,974
|
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
618,974
|
12
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES
¨
|
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
8.6%
|
14
|
TYPE OF REPORTING PERSON
IV
|
|
|
|
|
Item 1.
Security and Issuer.
This Statement on
Schedule 13D relates to the Common Shares (the “Shares”) of ESSA Pharma Inc. (the “Issuer”). The address
of the principal executive offices of the Issuer is Suite 720, 999 West Broadway, Vancouver, British Columbia, Canada, V5Z 1K5.
Item 2.
Identity and Background.
This Statement is
being jointly filed by: (i) Eventide Asset Management, LLC, a Delaware limited liability company registered as an investment adviser
with the U.S. Securities and Exchange Commission (“Eventide”); (ii) Finny Kuruvilla, M.D., Ph.D., a United States citizen
who is a Managing Partner and a control person of Eventide (“Kuruvilla”); (iii) Eventide Healthcare & Life Sciences
Fund (the “Healthcare & Life Sciences Fund”), a separate investment series of Mutual Fund Series Trust (the “Trust”),
an investment company registered with the U.S. Securities and Exchange Commission under the Investment Company Act of 1940, as
amended, for which Eventide serves as investment adviser; and (iv) Eventide Gilead Fund (the “Gilead Fund”), a separate
investment series of the Trust for which Eventide also serves as investment adviser. (Eventide, Kuruvilla, the Healthcare &
Life Sciences Fund and the Gilead Fund are sometimes also referred to herein individually as a "Reporting Person" and
collectively as the "Reporting Persons"). Further information regarding the identity and background of certain of the
Reporting Persons is set forth in Exhibit B which is attached hereto.
During the last five years,
none of the Reporting Persons, nor, to the best knowledge of the Reporting Persons, any of their respective executive officers,
their respective managing members or any persons controlling their respective managing members has: (1) been convicted in a criminal
proceeding (excluding traffic violations or similar misdemeanors) or (2) been party to a civil proceeding of a judicial or administrative
body of competent jurisdiction and, as a result of such proceeding, was or is subject to a judgment, decree or final order enjoining
future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation
with respect to such laws.
Item 3.
Source and Amount
of Funds or Other Consideration.
The Shares herein
reported as being beneficially owned by the Reporting Persons were acquired by Eventide directly acting solely on behalf of its
investment advisory clients. Eventide has purchased a total of 481,970 Shares in negotiated purchases and has acquired 904,000
warrants (the “Warrants”) for an aggregate consideration of $13,158,230 (exclusive of brokerage commissions). To the
best knowledge of the Reporting Persons, the funds used in such purchases were from Eventide’s existing and available investment
capital and none of the consideration for such Shares was represented by borrowed funds.
Item 4.
Purpose of Transaction.
The Reporting Persons have
acquired the Shares for investment purposes and will continue to analyze their investment in the Issuer on an ongoing basis. As
part of this investment analysis process, the Reporting Persons have engaged in discussions with management of the Issuer and the
Reporting Persons reserve the right to engage with third parties that may have an interest in the business affairs of the Issuer
in order to monitor their investment and consider possible strategic alternatives.
Effective as of May 14, 2019,
the Healthcare & Life Sciences Fund and the Gilead Fund each entered into a Waiver and Agreement to Exercise with the Issuer
with respect to the Warrants (the “Exercise Agreement”) pursuant to which the parties agreed to certain matters regarding
the terms of the
exercise of the Warrants in connection with
the Issuer’s proposed transaction with Realm Therapeutics plc (the “Realm Transaction”). The Healthcare &
Life Sciences Fund and the Gilead Fund each agreed to exercise the Warrants subject to the conditions provided for in the Exercise
Agreement, including certain conditions with respect to the timing of the approval of the Realm Transaction. A copy of the Exercise
Agreement is attached hereto as Exhibit C.
Depending upon such discussions
and consideration of strategic alternatives, the Reporting Persons could support one or more of the actions described in subparagraphs
(a) through (j) of Item 4 of Schedule 13D. The Reporting Persons reserve the right to formulate other purposes, plans or proposals
regarding the Issuer to the extent deemed advisable by the Reporting Persons in light of current market conditions generally and
specifically as they relate to the Issuer. The Reporting Persons further reserve the right to add to or reduce their holdings in
the Issuer at any time as circumstances warrant without prior notice.
Item 5. Interest in Securities of
the Issuer.
Based on the most recently
available filing information submitted to the Securities and Exchange Commission by the Issuer, there are 6,311,098 Shares currently
outstanding. For purposes of this filing, the Reporting Persons have calculated their beneficial ownership in accordance with Rule
13d-3(d)(1) based upon: (i) the 6,311,098 Shares outstanding and (ii) the total number of Shares issuable upon the exercise of
the Warrants that are deemed to be beneficially owned by the Reporting Persons. As of May 14, 2019, the Reporting Persons collectively
may be deemed to beneficially own 1,385,970 Shares, which represents 19.2% of the outstanding Shares. The total amount of Shares
deemed to be beneficially owned by the Reporting Persons: (1) includes the 232,996 Shares directly owned by the Healthcare &
Life Sciences Fund and assumes that the 534,000 Warrants held by the Healthcare & Life Sciences Fund have been fully converted
and (2) includes the 248,974 Shares directly owned by the Gilead Fund and assumes that the 370,000 Warrants held by the Gilead
Fund have been fully converted. The number of Shares which may be deemed to be beneficially owned by the Reporting Persons are
as follows:
Shares Deemed to be
Beneficially Owned By:
|
Nature of
Ownership
|
Percentage
of Class
|
(A)
Eventide
:
|
|
|
1,385,970
|
Sole Voting and Sole Dispositive Power (1)
|
19.2%
|
(B)
Kuruvilla:
|
|
|
1,385,970
|
Shared Voting and Shared Dispositive Power (2)
|
19.2%
|
(C)
Healthcare & Life
Sciences Fund
:
|
|
|
766,996
|
Shared Voting and Shared Dispositive Power (3)
|
10.6%
|
(D)
Gilead Fund
:
|
|
|
618,974
|
Shared Voting and Shared Dispositive Power (4)
|
8.6%
|
____________________
|
(1)
|
Such Shares are owned by investment advisory clients of Eventide. By reason of its investment advisory
relationship with such clients, Eventide is deemed to have sole voting and sole dispositive power over such Shares. The economic
interest in such Shares is held by such clients.
|
|
(2)
|
Because Kuruvilla is a Managing Partner and control person of Eventide, he could be deemed to share
the power to vote and dispose or direct the disposition of such Shares.
|
|
(3)
|
Such Shares are owned by the Healthcare & Life Sciences Fund. Because Eventide serves as investment
adviser to the Fund, the Fund may be deemed to share the power to vote and dispose or direct the disposition of such shares.
|
|
(4)
|
Such Shares are owned by the Gilead Fund. Because Eventide serves as investment adviser to the
Fund, the Fund may be deemed to share the power to vote and dispose or direct the disposition of such shares.
|
TRANSACTIONS
The Reporting Persons have
not effected any transactions in the Shares during the last sixty days.
Item 6.
Contracts, Arrangements,
Understandings or Relations With Respect to Securities of the Issuer.
Attached hereto as
Exhibit C is a copy of the Exercise Agreement entered into between the Issuer and the Healthcare & Life Sciences Fund and the
Gilead Fund effective as of May 14, 2019.
Item 7.
Materials Filed
as Exhibits.
The following exhibits
are attached hereto:
Exhibit
A - Joint Filing Agreement of the Reporting Persons
Exhibit
B - Executive Officers and Control Persons of the Reporting Persons
Exhibit
C – Waiver and Agreement to Exercise
In accordance
with Rule 13d-4 of the Securities Exchange Act of 1934, the Reporting Persons expressly disclaim the beneficial ownership of the
securities covered by this statement and the filing of this report shall not be construed as an admission by such persons that
they are the beneficial owners of such securities.
SIGNATURES
The undersigned
certify, after reasonable inquiry and to the best knowledge and belief of the undersigned, that the information set forth in this
Statement is true, complete and correct. The undersigned agree to the filing of this single Statement on Schedule 13D.
|
|
Eventide Asset Management, LLC*
|
|
|
|
Date: May 23, 2019
|
|
By: /s/ Peter J. Luiso
|
|
|
Name: Peter J. Luiso
|
|
|
Title: Chief Compliance Officer and General Counsel
|
|
|
|
|
|
|
|
|
Finny Kuruvilla, M.D., Ph. D.*
|
|
|
|
Date: May 23, 2019
|
|
By: /s/ Finny Kuruvilla, M.D., Ph. D.
|
|
|
Name: Finny Kuruvilla, M.D., Ph. D.
|
|
|
|
|
|
Mutual Fund Series Trust, on behalf of Eventide Healthcare & Life Sciences Fund*
|
|
|
|
Date: May 23, 2019
|
|
By: /s/ Jennifer Bailey
|
|
|
Name: Jennifer Bailey
|
|
|
Title: Secretary
|
|
|
|
|
|
Mutual Fund Series Trust, on behalf of Eventide Gilead Fund*
|
|
|
|
Date: May 23, 2019
|
|
By: /s/ Jennifer Bailey
|
|
|
Name: Jennifer Bailey
|
|
|
Title: Secretary
|
* The Reporting Persons disclaim beneficial
ownership in the shares represented herein except to the extent of their pecuniary interest therein.
EXHIBIT A
Joint Filing Agreement Among
Eventide Asset Management, LLC, Finny Kuruvilla,
M.D., Ph.D.,
Mutual Fund Series Trust, on behalf of Eventide
Healthcare & Life Sciences Fund and Eventide Gilead Fund
WHEREAS
, in accordance with Rule 13d-1(k)(1)
under the Securities and Exchange Act of 1934 (the "Act"), only one joint Statement and any amendments thereto need to
be filed whenever one or more persons are required to file such a statement or any amendments thereto pursuant to Section 13(d)
of the Act with respect to the same securities, provided that said persons agree in writing that such Statement or amendments thereto
is filed on behalf of each of them:
NOW, THEREFORE
, the parties hereto agree
as follows:
Eventide Asset Management, LLC, Finny Kuruvilla,
M.D., Ph. D., and Mutual Fund Series Trust, on behalf of the Eventide Healthcare & Life Sciences Fund and the Eventide Gilead
Fund, do hereby agree, in accordance with Rule 13d-1(k)(1) under the Act, to file a Statement on Schedule 13D relating to their
ownership of the Common Shares of the Issuer, and do hereby further agree that said Statement on Schedule 13D shall be filed on
behalf of each of them.
|
|
Eventide Asset Management, LLC*
|
|
|
|
Date: May 23, 2019
|
|
By: /s/ Peter J. Luiso
|
|
|
Name: Peter J. Luiso
|
|
|
Title: Chief Compliance Officer and General Counsel
|
|
|
|
|
|
|
|
|
Finny Kuruvilla, M.D., Ph. D.*
|
|
|
|
Date: May 23, 2019
|
|
By: /s/ Finny Kuruvilla, M.D., Ph. D.
|
|
|
Name: Finny Kuruvilla, M.D., Ph. D.
|
|
|
|
|
|
Mutual Fund Series Trust, on behalf of Eventide Healthcare & Life Sciences Fund*
|
|
|
|
Date: May 23, 2019
|
|
By: /s/ Jennifer Bailey
|
|
|
Name: Jennifer Bailey
|
|
|
Title: Secretary
|
|
|
|
|
|
Mutual Fund Series Trust, on behalf of Eventide Gilead Fund*
|
|
|
|
Date: May 23, 2019
|
|
By: /s/ Jennifer Bailey
|
|
|
Name: Jennifer Bailey
|
|
|
Title: Secretary
|
EXHIBIT B
OFFICERS AND CONTROL PERSONS OF THE REPORTING
PERSONS
Except where otherwise noted, each of the individuals
named below is a citizen of the United States with a principal business address as indicated below.
A. Eventide Asset Management, LLC
Eventide Asset
Management, LLC is an investment adviser registered with the U.S. Securities and Exchange Commission and organized as a limited
liability company under the laws of the State of Delaware. Its address is:
One International Place, Suite 4210
Boston, Massachusetts 02110
The officers of
Eventide Asset Management, LLC are:
Name
|
|
Title
|
Robin C. John
|
|
Chief Executive Officer
|
Finny Kuruvilla, M.D., Ph. D.*
|
|
Chief Investment Officer
|
Peter J. Luiso, Esq.
|
|
Chief Compliance Officer and General Counsel
|
*
Mr.
Kuruvilla is deemed to be a control person of Eventide Asset Management, LLC as a result of his ownership interest in the firm.
B. Mutual Fund Series Trust, on behalf of each of Eventide Healthcare
& Life Sciences Fund and Eventide Gilead Fund
Mutual Fund
Series Trust is an investment company organized as a business trust under the laws of the State of Ohio and it is registered with
the U.S. Securities and Exchange Commission. The Eventide Healthcare & Life Sciences Fund and the Eventide Gilead Fund are
each separate investment series of the Trust and share Officers and Trustees with the Trust. Its address is:
17645 Wright Street, Suite 200
Omaha, Nebraska 68130
Information
regarding the Trustees and Officers of Mutual Fund Series Trust is incorporated herein by reference to the Section titled “Trustees
and Officers” in the Statement of Additional Information included in Post-Effective Amendment No. 398 to the Registration
Statement on Form N-1A of the Trust as filed with the U.S. Securities and Exchange Commission on March 12, 2019.
EXHIBIT C
WAIVER
AND AGREEMENT TO EXERCISE
RE:
|
The common share purchase warrant of Essa Pharma Inc. (the “Company”) dated January 9, 2018 and issued In the name of Eventide Gilead Fund (“Eventide Gilead”) and the common share purchase warrant of the Company dated January 9, 2018 and issued in the name of Eventide Healthcare & Life Sciences Fund (together with Eventide Gilead, “Eventide”) (together, the “Warrants”)
|
AND RE:
|
The Implementation Agreement (the “Implementation Agreement”) to be entered into between the Company and Realm Therapeutics plc (“Realm”) pursuant to which, among other things, the Company will acquire all of the issued share capital of Realm pursuant to a court-approved scheme of arrangement under the U.K. Companies Act 2008 (the “Scheme”)
|
WHEREAS, section
2(e) of each of the Warrants provides that the Company shall not effect any exercise of the Warrants if Eventide would, in the
aggregate, beneficially own common shares of the Company in excess of the Beneficial Ownership Limitation (as defined in the Warrants);
AND WHEREAS, section
2(e) of each of the Warrants further provides that an increase in the Beneficial Ownership Limitation will not be effective until
the 61st day after notice of such increase is delivered by Eventide to the Company (the “Notice Period”);
AND WHEREAS, in
connection with the Implementation Agreement, Eventide and the Company have been in ongoing discussions regarding Eventide exercising
the Warrants, which exercise would require Eventide to provide notice of the increase in the Beneficial Ownership Limitation in
accordance with the timing requirements of the Notice Period;
AND WHEREAS, under
the terms of the Implementation Agreement, the Scheme will require approval of the shareholders of Realm (the “Shareholder
Approval”) at a meeting of shareholders of Realm currently anticipated to be held during the week of June 24, 2019;
AND WHEREAS, subject
to receipt of the Shareholder Approval, the Company wishes to have Eventide exercise the Warrants one Business Day prior to the
Court Hearing (as such terms are defined below) (the “Exercise Date”), which is currently scheduled to occur as soon
as practicable following receipt of the Shareholder Approval and which is prior to the expiry of the Notice Period;
AND WHEREAS, it
is acknowledged and agreed by the Company and Eventide that discussions regarding the exercise of the Warrants began prior to the
61st day before the Exercise Date;
AND WHEREAS, Eventide
is in the process of submitting a duly completed personal information form to the TSX Venture Exchange (the “TSXV”);
AND WHEREAS, Eventide
has agreed to accede to the Company’s request that it exercise the Warrants on the Exercise Date, subject to certain conditions,
and the Company and Eventide wish to waive the Notice Period to permit that exercise.
NOW THEREFORE, for
good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Eventide and the Company agree as
follows:
1.
Subject to the TSXV approving (i) the personal
information form submitted by Eventide or the TSXV granting a waiver from such requirement and (ii) Eventide becoming an “Insider”
of the Company within the policies of the TSXV, Eventide and the Company hereby agree to waive section 2(e) of the Warrants in
respect of the Notice Period. For greater certainty, this waiver is given only in respect of section 2(e) as it applies to the
Notice Period and all other terms of the Warrants shall otherwise continue in full force and effect.
2.
Eventide and the Company hereby ratify and confirm
that the Beneficial Ownership Limitation under the Warrants shall not exceed 19.99%.
3.
Subject to the Shareholder Approval of the Scheme
and the Company providing notice to Eventide that the Shareholder Approval has occurred, Eventide hereby agrees that it will exercise
all, but not less than all, of the Warrants effective as of the Exercise Date by delivering to the Company a duly completed and
executed notice of exercise in respect of each of the Warrants in the form attached as Exhibit “A” to the Warrants
(and for greater certainty, if Eventide for any reason fails to do so, then Eventide shall, by its signatures below, be deemed
to have exercised the Warrants as of the Exercise Date).
4.
For the purposes hereof:
(a)
“Business Day” means a day (other
than a Saturday, Sunday, public or bank holiday) on which banks are generally open for business in London, United Kingdom, New
York, United States and Vancouver, British Columbia, Canada;
(b)
“Court” means the High Court of Justice
in England and Wales; and
(c)
“Court Hearing” means the hearing
of the Court at which Realm will seek an order sanctioning the Scheme.
5.
This Waiver and Agreement to Exercise shall be
governed by and construed in accordance with the laws of the Province of British Columbia and the laws of Canada applicable therein.
6.
This Waiver and Agreement to Exercise may be executed
in any number of counterparts and all such counterparts taken together shall be deemed to constitute one and the same instrument.
[Remainder of this page intentionally left blank.]
DATED as of this 14th day of May, 2019.
EVENTIDE GILEAD FUND
|
EVENTIDE HEALTHCARE & LIFE
SCIENCES FUND
|
Per:
/s/ Finny Kuruvilla
Name: Finny Kuruvilla
Title: Portfolio Manager
|
Per:
/s/ Finny Kuruvilla
Name: Finny Kuruvilla
Title: Portfolio Manager
|
|
ESSA PHARMA INC.
|
|
Per:
/s/ David Wood
Name: David Wood
Title: Chief Financial Officer
|
ESSA Pharma (NASDAQ:EPIX)
Historical Stock Chart
From Mar 2024 to Apr 2024
ESSA Pharma (NASDAQ:EPIX)
Historical Stock Chart
From Apr 2023 to Apr 2024